Top 5 Compensation Packages in FY21 for Laboratory Tool Company CEOs
Top 5 Compensation Packages for FY21 for Laboratory Tool Company CEOs
The median amount of the top five compensation packages for CEOs of laboratory tool companies was $16 million last fiscal year. Although executive compensation is based a variety of factors, revenues grew double digits for all five CEOs’ companies last fiscal year, boosted by lab reopenings and the return of industrial and applied markets. For Thermo Fisher Scientific and Danaher, the two companies on the list with significant COVID-related revenue, pandemic-related sales remained vibrant as COVID-19 testing demand was solid and revenues for products used in manufacturing COVID-19 vaccines and therapies posted strong gains.
|Company||Executive||Title||FY21 Total Compensation ($M)|
|Thermo Fisher Scientific||Marc N. Casper||President and CEO||$21.2|
|Danaher||Rainer M. Blair||President and CEO||$17.2|
|Agilent Technologies||Michael R. McMullen||CEO||$16.0|
|Bio-Techne||Charles R. Kummeth||President and CEO||$15.9|
|Illumina||Francis A. deSouza||CEO||$14.3|
Executive compensation can be divided into short-term and long-term compensation. Short-term compensation consists of an executive’s salary, bonus and incentives. Long-term compensation consists of stock grants and options. In fiscal 2021, the executives on the list had a larger proportion of their pay in long-term compensation. The median share of long-term compensation was 71% compared to 29% for short-term compensation. Excluded from the calculations for our list are stock and option awards vested during the year.
Number 1: Marc N. Casper, Chairman, President, CEO, Thermo Fisher Scientific
At over $20 million, Mr. Casper recorded the biggest total compensation package in FY21 among lab tool company CEOs. This is not surprising given Thermo Fisher Scientific’s domination of the lab tool industry. In 2021, company revenues reached $39.21 billion, a 22% increase. Nonetheless, Mr. Casper’s total compensation amount was actually 20% lower than in 2020. Although his short-term compensation gained 14%, his long-term compensation declined 23%. But not counted in total compensation was the $21.3 million in stocks vested during the year.
Number 2: Ranier M. Blair, President and CEO, Danaher
In his first full year as President and CEO of Danaher, Mr. Blair pulled in more than $17 million in total compensation. This was a hefty 65% increase for him, led by an over 70% jump in long-term compensation. The increase in short term compensation was also impressive, showing a more than 50% gain. As the world’s second-largest lab tools company, Danaher posted annual revenues of $29.5 billion in annual revenues, up 32%.
Number 3: Michael R. McMullen, CEO, Agilent Technologies
Mr. McMullen ended fiscal 2021 with an executive compensation package topping $15 million. The 17% increase was led by a 91% boost in short-term compensation. This was primarily due to an 170% increase in cash incentives. But long-term compensation grew much slower, expanding just 2%. The company’s fiscal 2021 revenues rose 18% to $6.32 billion.
Number 4: Charles Kummeth, President and CEO, Bio-Techne
Unlike Thermo Fisher Scientific, Danaher and Agilent, Bio-Techne has annual revenues of less than $1 billion. Nonetheless, Mr. Kummeth made it to fourth on the top 5 compensation list, with over $15 million in short-term and long-term compensation combined. With a 38% boost, this was just behind Mr. Ranier for the fastest growth in total compensation among the top 5. The bulk of the increase came in the form of short-term compensation, which grew 6%. Furthermore, Mr. Kummeth realized gains from stock options and vested stocks of over $35 million.
Number 5: Francis A. deSouza, President and CEO
Mr. deSouza recorded more than $14 million in total compensation last year, up 22% from 2020. This included an 93% jump in short-term compensation. Contributing to this gain was an over 250% increase in incentives. Compared to his short-temp compensation, long-term compensation showed a more modest 10% increase. Illumina had an especially strong year, posting 40% sales growth to $4.5 billion.
An extensive review at executive compensation in the laboratory tool industry is available in the May 16, 2022 issue of Instrument Business Outlook (IBO).
- Dividends as an Indicator for Laboratory Tool Industry Companies in 2022
- Improving Drug Development: Molecular Devices and Cellesce Aim to Advance the Use of Organoids
- Danaher Investor Day 2022 Showcases Big Announcements and Focuses on Cytiva
- IBO 2022 Industrial Design Awards Announced
- The SDi Global Report Details Lab Tool Market Growth